Ecofuril 0.2 N30
Category
Diarrhea
Scope of the drug
Gastrointestinal tract
Release form
Capsules
Manufacturer country
Russia
Package quantity, pcs
thirty
Dosage form
Hard gelatin capsules, yellow
the contents of the capsules are yellow powder.
Structure
Active ingredient: nifuroxazide 200 mg.
Excipients: lactulose - 300 mg, microcrystalline cellulose - 58 mg, potato starch - 18 mg, magnesium stearate - 6 mg, sucrose - until the mass of the capsule contents is 630 mg.
Composition of a hard gelatin capsule: gelatin - up to 100%, water - 14-15%
cap: crimson dye [Ponso 4R] - 0.079801%, patented blue dye - 0.00165%, sunset dye - 0.093301%, titanium dioxide - 0.813158%
body: quinoline yellow dye - 0.583356%, sunset dye - 0.002565%, titanium dioxide - 0.974035%.
general description
Antimicrobial agent, nitrofuran
Special conditions
When treating diarrhea concurrently with nifuroxazide therapy, rehydration therapy (oral or intravenous) should be carried out in accordance with the patient's condition and the duration of the diarrhea.
During therapy with nifuroxazide, alcohol is not allowed.
Influence on the ability to drive vehicles and use mechanisms
The drug does not adversely affect the ability to drive vehicles and / or other mechanisms.
Drug interactions
Concomitant use of ethanol may cause hypersensitivity symptoms
Pharmacodynamics
Broad-spectrum antimicrobial agent - 5-nitrofuran derivative for the treatment of gastrointestinal infections.
Nifuroxazide blocks the activity of dehydrogenases and inhibits the respiratory chain, the tricarboxylic acid cycle and other biochemical reactions in the bacterial cell.
Destroys the membranes of sensitive bacteria, reduces the production of toxins by microorganisms.
It activates immunity, increases the activity of phagocytes and the titer of complement.
Effective against gram-positive microorganisms: Staphylococcus spp., Streptococcus spp .
gram-negative microorganisms: Salmonella spp., Klebsiella spp., Enterobacter spp., Escherichia coli, Shigella spp., Proteus spp., Haemophilus influenzae, Campilobacter spp., Edwarsiella spp., Citrobacter spp., Yibrioersin cholerae enter
Pharmokinetics
Nifuroxazide does not affect the state of the normal microflora of the human intestine.
In case of acute bacterial diarrhea, it restores intestinal eubiosis.
When infected with enterotropic viruses, it prevents the development of bacterial superinfection.
After oral administration, nifuroxazide is practically not absorbed from the gastrointestinal tract and has no systemic effect.
Antibacterial activity against susceptible species of bacteria is shown only in the intestinal lumen.
It is excreted unchanged by the intestines.
The rate of elimination depends on the dose of the drug and gastrointestinal motility.
Indications
- acute and chronic diarrhea of infectious genesis (without signs of helminthic invasion)
- chronic colitis and enterocolitis.
Contraindications
- hypersensitivity to nifuroxazide, other components of the drug, other derivatives of 5-nitrofuran
- deficiency of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption
- children's age up to 3 years (for this lekform).
There is no evidence of adverse effects on the fetus during pregnancy.
If necessary, with caution, the drug can be prescribed to pregnant women and women who are breastfeeding.
Side effects
Possibly: allergic reactions.
Dosage
200mg
Indications
0
Contraindications
- hypersensitivity to nifuroxazide, other components of the drug, other derivatives of 5-nitrofuran
- deficiency of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption
- children's age up to 3 years (for this lekform).
INN / Active ingredient
Nifuroxazide
Storage conditions and periods
In a place protected from moisture and light, at a temperature not exceeding 25 degrees.
Expiration date: 5 years
Specifications
Category
Diarrhea
Scope of the drug
Gastrointestinal tract
Release form
Capsules
Manufacturer country
Russia
Package quantity, pcs
thirty
Vacation conditions
Without recipe
Brand name
Avva Rus
The amount of the dosage form in the primary package
5 pieces.
Primary packaging type
Blister
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Antimicrobial agent - nitrofuran
Anatomical and therapeutic characteristics
A07AX03 Nifuroxazide
Dosage form
Capsules
Dosage (volume) of the substance in the preparation
nifuroxazide 200 mg.
Expiration date in days
1825
Package weight, g
45